RGNX · Insider Trading
REGENXBIO Inc.
Every open-market purchase and sale reported by RGNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-03 | Craig Malzahn | Chief Technology Officer | A | +27,777 | — |
| 2026-11-03 | Mitchell Chan | Chief Financial Officer | A | +24,305 | — |
| 2026-11-03 | Steve Pakola | Chief Medical Officer | A | +34,722 | — |
| 2026-11-03 | Patrick J. Christmas | Chief Strategy & Legal Officer | A | +34,722 | — |
| 2026-09-03 | Mitchell Chan | Chief Financial Officer | F | −4,902 | −$45.69K |
| 2026-09-03 | Craig Malzahn | Chief Technology Officer | F | −234 | −$2.18K |
| 2026-08-27 | Gregory Austin Ciongoli | Director | MIXED | +118,035 | +$949.38K |
| 2026-08-04 | Steve Pakola | Chief Medical Officer | F | −7,468 | −$72.36K |
| 2026-08-04 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | −4,699 | −$45.53K |
| 2026-07-06 | Curran Simpson | Chief Executive Officer | MIXED | −4,414 | −$67.80K |
| 2026-07-06 | Steve Pakola | Chief Medical Officer | MIXED | — | −$12.49K |
| 2026-07-01 | Steve Pakola | Chief Medical Officer | MIXED | −19,608 | −$400.10K |
| 2026-06-02 | Daniel Tasse | Director | A | +9,807 | — |
| 2026-06-02 | David C Stump | Director | A | +9,807 | — |
| 2026-06-02 | Argeris N Karabelas | Director | A | +9,807 | — |
| 2026-06-02 | Allan M. Fox | Director | A | +9,807 | — |
| 2026-06-02 | George V Migausky | Director | A | +9,807 | — |
| 2026-06-02 | Kenneth T. Mills | Director | A | +9,807 | — |
| 2026-06-02 | Alexandra Glucksmann | Director | A | +9,807 | — |
| 2026-06-02 | Jennifer Zachary | Director | A | +9,807 | — |
| 2026-06-02 | Jean Bennett | Director | A | +9,807 | — |
| 2026-05-13 | Steve Pakola | Chief Medical Officer | Sell | −15,309 | −$168.71K |
| 2026-03-12 | Steve Pakola | Chief Medical Officer | Sell | −5,124 | −$53.03K |
| 2026-02-03 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | −4,700 | −$52.45K |
| 2026-02-03 | Steve Pakola | Chief Medical Officer | F | −5,267 | −$58.78K |
| 2026-01-29 | Kenneth T. Mills | Director | MIXED | +3,247 | −$28.46K |
| 2026-01-08 | Curran Simpson | Chief Executive Officer | A | +144,864 | — |
| 2026-01-08 | Patrick J. Christmas | Chief Strategy & Legal Officer | A | +73,749 | — |
| 2026-01-08 | Craig Malzahn | Chief Technology Officer | A | +65,847 | — |
| 2026-01-08 | Steve Pakola | Chief Medical Officer | A | +65,847 | — |
| 2026-01-08 | Mitchell Chan | Chief Financial Officer | A | +73,749 | — |
| 2026-01-06 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | −9,793 | −$141.02K |
| 2026-01-06 | Steve Pakola | Chief Medical Officer | F | −18,247 | −$262.76K |
| 2026-01-06 | Craig Malzahn | Chief Technology Officer | F | −1,238 | −$17.83K |
| 2026-01-06 | Curran Simpson | Chief Executive Officer | F | −18,559 | −$267.25K |
| 2025-10-10 | Curran Simpson | Chief Executive Officer | Sell | −20,811 | −$262.63K |
| 2025-10-01 | Curran Simpson | Chief Executive Officer | Sell | −7,624 | −$76.47K |
| 2025-09-12 | Curran Simpson | Chief Executive Officer | Sell | −7,734 | −$77.49K |
| 2025-09-03 | Craig Malzahn | Chief Technology Officer | F | −234 | −$2.09K |
| 2025-09-03 | Mitchell Chan | Chief Financial Officer | F | −4,901 | −$43.77K |
| 2025-08-04 | Patrick J. Christmas | Chief Strategy & Legal Officer | F | −4,699 | −$38.48K |
| 2025-07-03 | Curran Simpson | Chief Executive Officer | F | −4,701 | −$38.69K |
| 2025-06-03 | Daniel Tasse | Director | A | +7,768 | — |
| 2025-06-03 | Jennifer Zachary | Director | A | +7,768 | — |
| 2025-06-03 | David C Stump | Director | A | +7,768 | — |
| 2025-06-03 | Jean Bennett | Director | A | +7,768 | — |
| 2025-06-03 | George V Migausky | Director | A | +7,768 | — |
| 2025-06-03 | Alexandra Glucksmann | Director | A | +7,768 | — |
| 2025-06-03 | Allan M. Fox | Director | A | +7,768 | — |
| 2025-06-03 | Argeris N Karabelas | Director | A | +7,768 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Allan M. Fox | Director | 751,346 | $6.12M |
| Kenneth T. Mills | Director | 495,925 | $4.04M |
| Curran Simpson | Chief Executive Officer | 343,418 | $2.80M |
| Patrick J. Christmas | Chief Strategy & Legal Officer | 240,690 | $1.96M |
| Steve Pakola | Chief Medical Officer | 240,263 | $1.96M |
| Olivier Danos | Chief Scientific Officer | 226,348 | $1.84M |
| Mitchell Chan | Chief Financial Officer | 147,120 | $1.20M |
| Craig Malzahn | Chief Technology Officer | 109,737 | $893.26K |
| Gregory Austin Ciongoli | Director | 64,628 | $526.07K |
| Jennifer Zachary | Director | 31,871 | $259.43K |
| George V Migausky | Director | 28,861 | $234.93K |
| Argeris N Karabelas | Director | 28,861 | $234.93K |
| David C Stump | Director | 28,861 | $234.93K |
| Daniel Tasse | Director | 28,861 | $234.93K |
| Alexandra Glucksmann | Director | 28,861 | $234.93K |
| Jean Bennett | Director | 28,861 | $234.93K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RGNX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.